IE912905A1 - Antiallergy agents - Google Patents

Abstract

Platelet activating factor antagonists of formula (I), where X is -CH=CH- or S, R<1> is a cyano, carboxy, carboxylic ester or optionally substituted carbamoyl or amido group and R<2> is H, halogen or C1-C4 alkyl.

Description

ANTIALLERGY AGENTS This invention relates to indane and cyclopentanothiophene derivatives which are potent, orally active antagonists of platelet activating factor and as such have clinical utility for treating allergic and inflammatory conditions such as asthma and arthritis respectively.

Platelet activating factor (PAF, l-0-alkyl-2acetyl-sn-glyceryl-3-phosphorylcholine) is an ether phospholipid whose structure was first elucidated in 1979. It is produced by, released from and interacts with many pro-inflammatory cells, platelets and the kidney. In addition to potent platelet aggregating activity, PAF exhibits a wide spectrum of biological activities elicited either directly or via the release of other powerful mediators such as thromboxane A2 or the leukotrienes. In vitro. PAF stimulates the movement and aggregation of neutrophils and the release therefrom of tissue-damaging enzymes and oxygen radicals. These activities contribute to actions of PAF in vivo consistent with it playing a significant role in inflammatory and allergic responses. Thus, intradermal PAF has been shown to induce an inflammatory response, with associated pain, accumulation of inflammatory cells and increased PLC 531 vascular permeability, comparable with the allergic skin reaction following exposure to allergen.

Similarly, both the acute broncho-constriction and chronic inflammatory reactions elicited by allergens in asthma can be mimicked by intratracheal administration of PAF. Accordingly agents which antagonise the actions of PAF and, consequently also prevent mediator release by PAF, will have clinical utility in the treatment of a variety of allergic and inflammatory conditions such as asthma and arthritis, respectively.

In addition to the above, PAF has been implicated as being involved in a number of other medical conditions. Thus in circulatory shock, which is characterised by systemic hypotension, pulmonary hypertension and increased lung vascular permeability, the symptoms can be mimicked by infusion of PAF. This coupled with evidence showing that circulating PAF * levels are increased by endotoxin infusion indicate that PAF is a prime mediator in certain forms of shock.

Intravenous infusion of PAF at doses of 20-200 pmol — 1 —1 kg min into rats results in the formation of extensive haemorrhagic erosions in the gastric mucosa and thus PAF is the most potent gastric ulcerogen yet described whose endogenous release may underlie or contribute to certain forms of gastric ulceration. Psoriasis is an inflammatory and proliferative disease PLC 531 characterised by skin lesions. PAF is pro-inflammatory and has been isolated from lesioned scale of psoriatic patients indicating PAF has a role in the disease of psoriasis. And finally, increasing evidence supports a potential pathophysiological role for PAF in cardiovascular disease. Thus recent studies in angina patients show PAF is released during atrial pacing and, in pigs, intracoronary injection of PAF induces a prolonged decrease in coronary flow while in guinea pig hearts it induces regional shunting and ischaemia. PAF has also been shown to initiate thrombus formation in a mesenteric artery preparation both when administered exogenously and when released endogenously. More recently PAF has been shown to play a role in brain ischaemia induced in animal models of stroke.

Thus compounds of the invention, by virtue of their ability to antagonise the actions of PAF, could well be of value in the treatment of any of the above conditions.

According to the invention there are provided compounds of formula (I): PLC 531 wherein X is -CH=CH- or S; R1 is -COOR3, -CN, -CONR4R5 or -NR6COR3 . where R is H, C-C,. alkyl, C -C_ cycloalkyl, or Id 3 / C1~C4 alkyl substituted by phenyl; R and R are each independently H, C^Cg alkyl which may optionally be substituted by a hydroxyl or C^-C^ alkoxy group, C^-C^ cycloalkyl, phenyl or pyridyl, said phenyl and pyridyl groups being optionally substituted by up to three groups independently selected from halo, hydroxy, -CF3, alkyl and C^-alkoxy, or R and R together with the nitrogen atom to which they are attached represent a pyrrolidine, piperidine or morpholine ring; R is H or C1-C4 alkyl; and R is H, halo, or C1~C4 alkyl; and their pharmaceutically acceptable salts.

In the definitions given herein the term halo means fluoro, chloro, bromo or iodo. Alkyl and alkoxy groups of 3 or more carbon atoms may be straight or branched-chain. 1 .

R , when present, is preferably H and R is preferably at the 2-position of the indane nucleus (when X is -CH=CH-) or the 5 position of the cyclopentanothiophene nucleus (when X is -S-).

PLC 531 Examples of R groups are cyano, carboxy, ethoxycarbonyl, t-butylcarbonylamino and group -CONR R 4 5 where R and R together form a pipendino or 4 5 morpholino group or R and R are independently selected from H, t-butyl, cyclopentyl, cyclohexyl, methyl, ethyl, propyl, isopropyl, pyridyl and pyridyl substituted by a methyl group. A particularly preferred compound is 2-(2-methylimidazo[4,5-c]pyrid1- yl)-5-(N-pyrid-2-yl-carbamoyl)-cyclopentano[b]thiophene. Other particularly preferred compounds are: 2- (Ν,Ν-dipropylcarbamoyl)-5-(2-methylimidazo[4,5-c]pyrid-l-yl)indane and 2-(N,N-dicyclopentylcarbamoyl)-5-(2-methylimidazo[4,5-c]pyrid-l-yl)indane.

The compounds of formula (I) contain at least one asymmetric centre and will therefore exist as one or more pairs of enantiomers, and such pairs of individual isomers may be separable by physical methods, e.g. by fractional crystallisation or chromatography of the parent compounds or of a suitable salt or derivative thereof. Alternatively, particular isomers may be prepared using the corresponding optical isomers of the precursors used in preparation of compounds of the invention. The invention includes all the enantiomers of the compounds of formula (I) whether separated or not.

The pharmaceutically acceptable acid addition salts of the compounds of formula (I) are those formed PIC 531 from acids which form non-toxic acid addition salts, for example the hydrochloride, hydrobromide, sulphate or bisulphate, phosphate or acid phosphate, acetate, citrate, fumarate, gluconate, lactate, maleate, succinate, tartrate, methanesulphonate, benzenesulphonate and p-toluenesulphonate.

When X is -CH=CH- and R1 is CN, the compound of formula (I) may be obtained by cyclising the corresponding compound of formula (II), for example by treating it with acetic anhydride in the presence of acetic acid: (ri) This reaction may be carried out by heating the compound (II) with acetic anhydride and glacial acetic acid, followed by separation of the product by conventional methods.

PLC 531 The corresponding compound (III) may be obtained by hydrolysing compound (I) in which R1 is CN and X is -CH=CH-, generally in the presence of an alkali, followed by acidification: (III) Compound (III) may be esterified by conventional . 3 methods to produce corresponding compounds in which R is C1~Cg alkyl, c3_c7 cycloalkyl or C^-C4 alkyl substituted by phenyl.

* When R1 is CONR4R5 and X is -CH=CH- the compound of formula (I) may be prepared from the acid (III) by converting the latter to the corresponding carbonyl chloride, for example by treatment with oxalyl chloride, and treating the product with the appropriate amine, or sodium salt of the amine: PLC 531 (III) When R1 is NR6COR^ the acid (III) may first be converted to a corresponding compound (IV) in which R1 is NH2, for example by treatment with diphenylphosphorylazide: PLC 531 (PhO)2P(O)N3 (IV) The amine (IV) may then be converted to the carbonylamino compound (V) in which R6 is H by reaction with the appropriate carbonyl chloride: PIT 531 (V) Compounds in which R6 is alkyl may be made by * alkylating compounds of formula (V) in known manner.

The novel intermediates (IV) constitute a further aspect of the present invention.

The compounds of formula (II) may be prepared from the corresponding cyanoindanes by the synthesis shown in Scheme 1. This synthesis entails nitration of the cyanoindane, for example with fuming nitric acid in acetic anhydride, followed by reduction of the nitro group, suitably with hydrogen in the presence of a PIC 531 palladium/carbon catalyst. The amine so formed may then be reacted with the appropriate chloro-nitropyridine derivative and the nitro group in the compound produced is reduced catalytically to give the compound of formula (II).

Scheme 1 CN HNO, CN NO, h2 Pd/C PLC 531 . 1 3 When X is -S- and R is -COOR the cyclopentano [b]thiophenes of formula (I) may be made firstly by reacting a 3-cyclopentanone carboxylic ester with sulphur and a cyanoacetate to form a cyclopentano[b] thiophene substituted by amino and carboxylate groups of formula (VI): In the above formulae group R is an optionally substituted alkyl group such as ethyl or t-butyl. The * reaction may be conducted by heating the reagents together in the presence of a solvent such as dimethylformamide and a base such as triethylamine.

The compound of formula (VI) may then be reacted with 4-chloro-3-nitropyridine in the presence of a base such as sodium bicarbonate, followed by reduction with hydrogen and a palladium catalyst to form a compound of formula (VII) below, ring closure with acetic anhydride and removal of the carboxylate group on the thiophene ring for example if R = t-butyl by treatment with a PIC 531 strong acid such as trifluoroacetic acid followed by heating with copper in the presence of quinoline.

These process steps are illustrated by Scheme 2 below: Scheme 2 CJ PLC 531 PLC 531 The corresponding compounds of formula (I) in 3 . which R is H may be obtained by hydrolysing the ester produced by the synthesis of Scheme 2 by conventional methods. The compounds of formula (I) in which X is 1 . 4 5 6 3 -S- and R is CONR R or NR COR may be prepared from those in which R1 is CO2H by methods analogous to those described above for compounds in which X is -CH=CH-.

The acid in which R1 is CO2H and X is S may be converted to the corresponding nitrile by conventional methods.

In the above synthesis of compound (VI) the CO2R group may be attached to the cyclopentane ring of compound (VI) at either the 4- or the 5-position of the cyclopentano[b]thiophene and in practice a mixture of both isomers is produced. These isomers may be separated by conventional methods, alternatively the further synthetic steps for obtaining compounds of formula (I) may be carried out on the mixture and the mixture of end products separated.

The activity of the compounds of the invention is shown by their ability to inhibit the platelet aggregating activity of PAF in vitro. Testing is performed as follows: Blood samples are taken from either rabbit or man into 0.1 vol disodium ethylenediamine tetraacetic acid buffer and the samples centrifuged for 15 minutes to PLC 531 obtain platelet rich plasma. The plasma is further centrifuged to give a platelet pellet which is washed with a buffer solution (4mM KH2PC>4, 6mM Na2HPC>4, 100 mM NaCl, 0.1% glucose and 0.1% bovine serum albumin, pH 7.25) and finally resuspended in buffer solution to a g concentration of 2 x 10 platelets/ml. A sample (0.5 ml) is pre-incubated for two minutes at 37°C in a Paton aggregometer with stirring, either with vehicle alone, or with vehicle containing the particular compound under test. PAF is added at a sufficient concentration to give a maximum aggregating response in the absence _g — 9 of test compound (10 to 10 molar), and the platelet aggregation is measured by following the increase in light transmission of the solution. The experiment is repeated in the presence of test compound at a range of concentrations and the concentration of compound required to reduce the response to 50% of its maxiumum value is recorded as the ICcn value. □ u The activity of the compounds of formula (I) is also demonstrated in vivo by their ability to protect mice from the lethal effect of an injection of PAF. A mixture of PAF (50 /ig/kg) and DL-propranolol (5 mg/kg) in 0.9% w/v sodium chloride is injected (0.2 ml) via a tail vein immediately prior to the PAF/propranolol injection or administered orally by gavage two hours earlier. The compounds are tested at several doses in groups of 5 mice and the dose which reduces mortality to 50% is recorded as the PDCM value. □ 0 PLC 531 For therapeutic use the compounds of the formula (I) will generally be administered in admixture with a pharmaceutical carrier selected with regard to the intended route of administration and standard pharmaceutical practice. For example, they may be administered orally in the form of tablets containing such excipients as starch or lactose, or in capsules or ovules either alone or in admixture with excipients, or in the form of elixirs or suspensions containing flavouring or colouring agents. They may be injected parenterally, for example, intravenously, intramuscularly or subcutaneously. For parenteral administration, they are best used in the form of a sterile aqueous solution which may contain other substances, for example, enough salts or glucose to make the solution isotonic with blood.

For administration to man in the curative or prophylactic treatment of allergic bronchial conditions and arthritis, oral dosage of the compounds will generally be in the range of from 2-1000 mg daily for an average adult patient (70 kg). Thus for a typical adult patient, individual tablets or capsules contain from 1 to 500 mg of active compound, in a suitable pharmaceutically acceptable vehicle or carrier.

Dosages for intravenous administration would typically be within the range 1 to 10 mg per single dose as required. For the treatment of allergic and bronchial PLC 531 hyper-reactive conditions, inhalation via a nebuliser or aerosol may be the preferred route of drug administration. Dose levels by this route would be within the range 0.1 to 50 mg per single dose as required. In practice the physician will determine the actual dosage which will be most suitable for an individual patient and it will vary with age, weight and response of the particular patient. The above dosages are exemplary of the average case but there can, of course, be individual instances where higher or lower dosage ranges are merited, and such are within the scope of this invention.

Thus in a further aspect the invention provides a pharmaceutical composition comprising a compound of the formula (I) or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable diluent or carrier.

The invention also includes a compound of the formula (I) or a pharmaceutically acceptable salt thereof, for use in medicine, in particular in the treatment of allergic and inflammatory conditions in a human being.

The preparation of the compounds of the invention is further illustrated by the following Examples.

PLC 531 Example 1 2-Cyano-5-(2-methylimidazor4,5-c)pyrid-l-yl) indane UNO-) CN 7— Ac 20 02N- -CN i’d/C -> JO h2n -CN CN CN (a) Fuming nitric acid (40 ml, 1.5 g/ml) was added dropwise with stirring to acetic anhydride (80 ml) keeping the temperature of the mixture at 0°C. After the addition was complete 2-cyanoindane (11.33 g, 79.5 * mmol, J. Chem. Soc. (B), (1969), 1197) was added dropwise with stirring over 30 minutes maintaining the reaction temperature between -5° and 0°C. The mixture was stirred for a further 15 minutes then poured onto ice. The mixture was extracted with dichloromethane (4 x 150 ml) and the extracts were washed with saturated aqueous sodium bicarbonate (3 x 150 ml), dried (MgSC>4) and concentrated under reduced pressure. The residue was recrystallised from ethanol to give 2-cyano-5-nitro-indane (12.09 g, 81%) as a yellow solid, m.p. 80-82°C.

PLC 531 1H NMR (300 MHz, CDC13) 6 = 3.32-3.53 (5H, complex), 7.43 (lH,d, J =9Hz), 8.15 (lH,s), 8.17 (lH,d,J = 9Hz) p.p.m. (b) A solution of 2-cyano-5-nitro-indane (11.90 g, 63.3 mmol) in methanol/dichloromethane = 1:1 (200 ml) was hydrogenated over 10% palladium on charcoal (1.2 g) at 30 p.s.i. and 20°C for 5 hours. The catalyst was filtered off and the filtrate was concentrated under reduced pressure to give 5-amino-2-cyano-indane (10.4 g, ca quantitative) which was used directly for the next reaction. A portion, recrystallised from ethanol, formed pinkish needles, m.p. 73-76°C. 1H NMR (300 MHz, CDCip 6 = 3.11-3.30 (5H, complex), 3.65 (2H, br s), 6.58 (lH,d,J=8Hz), 6.61 (lH,s), 7.03 (lH,d,J=8Hz) p.p.m. (c) 4-Chloro-3-nitropyridine (11.46 g, 72.3 mmol) was added to a suspension of 5-amino-2-cyano-indane (10.4 g, 65.7 mmol) in ethanol (150 ml) at room temperature. The mixture was stirred overnight at room temperature and then poured into excess ice-cold aqueous ammonia. The yellow solid was filtered off, partially digested in hot ethanol (150 ml), cooled, and re-filtered to give 2-cyano-5-(3-nitropyrid-4-ylamino)indane (13.61 g, 74%).

PLC 531 1H NMR (300 MHz, CDC13) 8 = 3.31-3.48 (5H, complex), 6.92 (lH,d,J=5Hz), 7.15(1H,d,J=6Hz), 7.19(lH,s), 7.37(1H,d,J=6Hz), 8.28(lH,d,H=5Hz), 9.31(lH,s), 9.64(1H, br s) p.p.m. (d) 2-Cyano-5-(3-nitropyrid-4-ylamino)indane (12.46 gm, 44.5 mmol) was suspended in methanol/ dichloromethane = 1:1 (750 ml) and hydrogenated at 20°C and 30 p.s.i. over 10% palladium on charcoal (1.25 g) for 2 hours. The catalyst was filtered off and the filtrate was concentrated under reduced pressure to give 5-(3-aminopyrid-4-ylamino)-2-cyano-indane (12.28 g, ca quantitative) as a yellow solid, m.p. 98-100°C. 1H NMR (300 MHz, dmso-d^) 8 = 3.03-3.35(4H,m), 3.54 D (lH,p,J=7Hz), 4.1O(1H, br s), 4.64(2H, br s), 6.84(lH,d,J=5Hz), 6.92(1H,dd,J=7 and 2Hz), 7.00(lH,d,J=2Hz), 7.18(1H,d,J=7Hz), 7.60(2H,d,J=5Hz), 7.84(lH,s)p.p.m. (e) A mixture of 5-(3-aminopyrid-4-ylamino)-2cyano-indane (12.28 g, ca 44.5 mmol from step (d) above), acetic acid (70 ml) and acetic anhydride (70 ml) was heated at reflux under nitrogen for 1.75 hours, cooled, and concentrated under reduced pressure. The residual brown gum was dissolved in 2N hydrochloric PIT 531 acid (40 ml) and washed with ethyl acetate (50 ml).

The aqueous layer was rendered basic by the addition of 2N aqueous sodium hydroxide, and the product was extracted into dichloromethane (4 x 50 ml). The combined extracts were washed with water (50 ml), dried (MgSO4) and concentrated under reduced pressure.

The residue was purified by column chromatography (silica gel, 60-200μ), eluting with ethyl acetate/ methanol=7:1. Fractions containing product were combined and concentrated to give a brown gum, which was recrystallised from ethyl acetate/methanol, to give the title compound as an off-white powder (9.674 g, 79%), m.p. 174-176°C.

Analysis %:Found; C,74.40; H,5.17; N,20.72.

C17H14N4 re*3u;*-res C,74.43; H,5.14; N,20.42.

Example 2 -(2—MethylimidazoΓ4,5-clpyrid-l-yl)indan-2carboxylic acid PLC 531 A mixture of 2-cyano-5-(2-methylimidazo[4,5-c]pyrid-l-yl)-indane (Example 1, 739 mg, 2.70 mmol), 50% aqueous sodium hydroxide (1 ml) and methanol (6 ml) was heated at reflux under nitrogen for 9 hours, cooled, poured onto ice, and the pH of the solution was adjusted to pH5 by the addition of dilute hydrochloric acid. The product precipitated as a white solid, (426mg, 54%) which was filtered off and dried in vacuo to give the title compound, m.p. 264-267°C.

Analysis %:Found: C,68.91; H,5.08; N,14.08. . 1/5 H20 requires C,68.76; H,5.23; N,14.15.

Example 3 Ethyl 5-(2-MethylimidazoΓ4,5-clpyrid-l-yl)indane2-carboxylate PLC 531 Oxalyl chloride (1.3ml, 14.9mmol) was added dropwise over 5 min to a stirred suspension of 5-(2-methylimidazo[4,5-c]pyrid-l-yl) indane-2carboxylic acid (Example 2, 1.46g, 5.0 mmol) in dry dichloromethane (20 ml) under nitrogen at room temperature. After being stirred for lh, the resulting solution was concentrated under reduced pressure, redissolved in dry dichloromethane (20 ml) and a mixture of ethanol (0.352 ml, 6.0 mmol) and triethylamine (0.692 ml, 5.0 mmol) was added at room temperature. After a further lh, the solution was washed with saturated aqueous sodium bicarbonate (30 ml) , dried (MgSC>4) , and concentrated under reduced pressure. The residue was purified by flash chromatography, eluting with ethyl acetate:methanol =4:1 to give the title compound as a colourless gum, 1.4g (88%). The fumarate salt had m.p. 193-194°C Λ (methanol).

Analysis %:Found: C,63.17; H,5.38; N,9.47 C19H19N3°2-C4H4°2 re9uires; C,63.15; H,5.30; N,9.61 PLC 531 Example 4 2-(N-tert-Butylcarbamoyl)-5-r2-methylimidazoΓ 4,5-clpyrid-l-vllindane -[2-Methylimidazo[4,5-c]pyrid-l-yl]indan-2carboxylic acid (Example 2, 587 mg, 2 mmoles) was suspended in dry dichloromethane (15 ml). Oxalyl chloride (760 mg, 6 mmoles) was added followed by Λ N,N-dimethylformamide (10 μΐ). The mixture was stirred at room temperature for 1 hour to give a pale yellow solution. The solvent was removed under reduced pressure and the resulting 5-[2-methylimidazo[4,5-c]pyrid-l-yl]indan-2-carbonyl chloride was redissolved in dichloromethane (15 ml). tert-Butylamine (438 mg, 6 mmoles) in dichloromethane (3 ml) was added over 5 minutes and the reaction mixture was stirred at room temperature for 1 hour.

PLC 531 Saturated sodium bicarbonate (20 ml) was added and the mixture stirred at room temperature for 1 hour.

The dichloromethane layer was separated, dried over magnesium sulphate and the solvent removed under pressure. The residual foam was chromatographed over silica gel (40-63 μ), eluting with 15% methanol in ethyl acetate. Fractions containing product were evaporated to give a foam (500 mg) which was dissolved in ether/ethyl acetate = 3:1 (20 ml), filtered and allowed to crystallise. The precipitated solid was filtered and dried in vacuo yielding the title compound as a white solid (345 mg, 50%), m.p. 152-154°C.

Analysis %: Found: C,71.99; H,7.07; N,15.82.

C21H24N4° rei3uires C,72.39; H,6.94; N,16.08.

Examples 5-14 The compounds of Table 1 were made by the method of Example 3 using the appropriate nucleophile, and the acid chloride derived from the acid described in Example 2.

PLC 531 Table 1 ί II <-o o in CM 2.55(3H,s), 3.47 (5H,m), s S -P 3 co n G T3 8.39(lH,d,J=5Hz) , 8.47 1 8 11.27(lH,s) p.p.m. a in rd K (N σ» o r-~ J=8Hz), 7.22(lH,s), Ό 3 CO in co «Γ 3 IHz), 9.06(lH,s), Formula (for analysis) υ • E KO Yield o¥> rH pf1 W K o pT1 Example rH PIC 531 Example 15 (2R,2'S) and (2S,2'S) N-(2-Hydroxy-4-methylpentyl) -5—(2-methylimidazoΓ4,5-c1pyrid-l-yl)indane-2carboxamide CH CH A solution of 5-(2-methylimidazo[4,5-c]pyrid1-yl)indane-2-carbonyl chloride (Example 4, 0.93g, 3.0 mmol) in dry dichloromethane (20 ml) was prepared. A mixture of triethylamine (0.42 ml, 3.0 mmol) and S-l-amino-2-hydroxy-4-methylpentane (350 mg, 3.0 mmol) was added with stirring at room temperature. After 13h, the mixture was treated with saturated aqueous sodium bicarbonate (30 ml) and the products were extracted into dichloromethane (3 x 30 ml). The combined extracts were dried (MgSO^), concentrated under reduced pressure and purified by flash chromatography (gradient elution with ethyl acetate/methanol/diethylamine) to afford two main product fractions.

PLC 531 The faster running diastereomer (Rf = 0.25, EtOAc/MeOH = 3:1) was a light brown foam, 360 mg (31%), m.p. 67 °C. 1H NMR (300 MHz, CDCip δ = 0.87 (3H,d,J=6Hz), 0.91 (3H,d,J=6Hz), 1.22 (lH,m), 1.39 (lH,m), 1.71 (lH,m), 2.48 (3H,s), 3.10 (lH,m), 3.26 (5H,m), 3.53 (lH,m), 3.80 (lH,m), 6.11 (IH, br s), 7.02 (IH,d,J=5Hz), 7.06 (lH,d,J=8Hz), 7.10 (1H,S), 7.35 (IH,d,J=8Hz), 8.30 (lH,d,J=5Hz), 8.97 (1H,S) p.p.m.

The slower running diastereomer (Rf = 0.06, EtOAc/MeOH = 3:1) was repurified by flash chromatography (gradient elution with dichloromethane/ methanol) to give a brown solid (324mg, 28%), m.p. 102 °C.

XH NMR (300 MHz, CDC13) δ = 0.86 (3H, d, J=6Hz) , 0.90 (3H,d,J=6Hz), 1.22 (lH,m), 1.66 (2H,m), 2.47 (3H,s), 3.06-3.48 (7H, complex), 3.79 (lH,m), 7.06 (3H,m), 7.35 (lH,d,J=8Hz), 8.30 (lH,d,J=5Hz), 8.97 (lH,s), p.p.m.

PLC 531 Example 16 N-Cyclohexyl-N-(2-propyl)-5-(2-methylimidazor 4,5-c1 pyrid-l-yl)indane-2-carboxamide A mixture of cyclohexylisopropylamine (0.56g, 4.0 mmol) and sodium hydride (163mg, 60% dispersion in oil, 4.0 mmol) in 8ml dry tetrahydrofuran was stirred at room temperature under nitrogen for 15 mins. A suspension of 5-(2-methylimidazo[4,5-c]pyrid-l-yl) indane-2-carbonyl chloride (Example 4, 0.64g, 2.0 mmol) in dry tetrahydrofuran (8ml) was added, and the mixture was stirred at room temperature for 2h. The solvent was removed under reduced pressure, and the residue partitioned between dichloromethane and saturated aqueous sodium bicarbonate. The organic layer was separated, dried (MgSC>4) , and concentrated under reduced pressure. The residue was purified by flash PIC 531 chromatography (gradient elution with dichloromethane/ methanol) followed by chromatography on silica gel (20-40μ), eluting with ethyl acetate: methanol:cone, aqueous ammonia = 94:5:1, to give the title compound, mg (4%). m.p. (fumarate salt) 100°C. 1H NMR (300 MHz, dmso-d^) δ = 0.95-1.39 (4H,m), 1.13 D (3H,d,J=6Hz), 1.23 (3H,d,J=6Hz), 1.45-1.70 (6H,m), 2.39 (3H,s), 3.02-3.45 (5H,m), 3.63 (2H,m), 6.52 (2H,s), 7.09 (lH,d,J=5Hz), 7.23 (1H,d,J=8Hz), 7.31 (1H,S), 7.37 (lH,d,J=8Hz), 8.20 (lH,d,J=5Hz), 8.81 (lH,s) p.p.m. Analysis %:- Found: C, 64.78; H, 6.48; N, 8.80C27H32N4°·3/4 fumarate c 64.80; H, 6.42; N, 9.16% \ H2O requires: Example 17 N.N-Dicvclopentvl-5-(2-methvlimidazo Γ 4,5-clpyrid-l-yl)indane-2-carboxamide PIC 531 A mixture of dicyclopentylamine (306 mg, 2.0 mmol) and sodium hydride (80 mg, 60% dispersion in oil, 2.0 mmol) in 8 ml of dry tetrahydrofuran was stirred under nitrogen at room temperature for 15 minutes. A suspension of 5-(2-methylimidazo[4,5-c]pyrid-lyl)indane-2-carbonyl chloride (Example 4, 312 mg, 1.0 mmol) in dry tetrahydrofuran (4 ml) was added and the mixture was stirred for 18 hours. The solvent was removed under reduced pressure, and the residue was dissolved in dichloromethane (50 ml) and washed with saturated aqueous sodium bicarbonate (30 ml). The organic solution was dried (MgSO4) and concentrated under reduced pressure. The residue was purified by flash chromatography (eluting with ethyl acetate/methanol = 4:1) followed by preparative h.p.l.c. (Cj8 silanised silica, eluting with methanol/water - 9:1). The product was isolated as its fumarate salt, a white solid (38 mg, 9%) m.p. 133°C.

Analysis %:Found: C,64.78; H,6.48? N,8.80; C27H32N4°·3/2 W4·1/2 H2°: C,64.80; H,6.42; N,9.16.

PLC 531 Example 18 (a) 2-Amino-5-(2-methylimidazo[4,5-clpyrid-l-yl)indane -[2-Methylimidazo[4,5-c]pyrid-l-yl]indan-2carboxylic acid (Example 2, 1.17 g, 4 mmoles) was suspended in toluene (8 ml). Triethylamine (444 mg, 4.4 mmoles) and diphenylphosphoryl azide (1.21 g, 4.4 mmoles) were added and the mixture was heated at 100°C for 20 minutes. The reaction mixture was cooled and treated with IM sodium hydroxide (30 ml). The aqueous phase was separated and washed with toluene (30 ml), neutralised (pH7) with 2M hydrochloric acid and extracted with dichloromethane (10 x 60 ml). The extracts were combined and dried (MgSO4) and the solvent removed in vacuo. The product was chromatographed over silica gel (40-63μ) eluting with diethylamine:methanol:ethyl acetate = 5:10:85.

Fractions containing product were evaporated, yielding the title compound as an off-white foam, (870 mg, 82%).

PIC 531 1H NMR (300 MHz), CDCl3), δ = 2.00(2H,br), 2.54(3H,S), 2.82(2H,m), 3.21(2H,m), 3.96(lH,m), 7.05-7.21(3H,m), 7.39(1H,d,J=6Hz), 8.36(1H,d,J=4Hz), 9.06(lH,s), p.p.m. (b) 2-(tert-Butylcarbonylamino)-5-(2-methylimidazoΓ 4,5-c1pyrid-l-yl)indane 2-Amino-5-(2-methylimidazo[4,5-c]pyrid-l-yl]indane (264 mg, 1 mmole) was dissolved in dichloromethane (5 ml) and pivaloyl chloride (132 mg, 1.1 mmole) and triethylamine (111 mg, 1.1 mmole) were added. The reaction was stirred at room temperature for 2 hours.

The dichloromethane solution was washed with saturated sodium bicarbonate (10 ml), dried (MgSO4), and the solvent removed in vacuo. The crude product was chromatographed over silica gel (40-63 μ) eluting with diethylamine:methanol:ethyl acetate = 3:3:94, and the fractions containing product were evaporated.

PLC 531 The foam obtained (210 mg) was dissolved in methanol (5 ml), fumaric acid (70 mg) added and the solvent removed in vacuo. The resulting white foam was then sonicated in a mixture of ethyl acetate/ether = 1:3 (10 ml). The white solid was filtered off and dried, yielding the title compound as the fumarate salt (92 mg, 20%), m.p. 110-120°C.

Analysis %:Found C,64.32; H,6.42; N,11.71; C21H24N4O-C4H4°4 requires C,64.64; H,6.08; N,12.06.

!» PLC 531 Example 19 -Ethoxycarbonyl-2-(2-methylimidazof 4,5-c1pyrid-l-yl) -cyclopentanorblthiophene and 6-ethoxycarbonyl-2-(2methylimidazo-Γ4,5-clpyrid-l-yl)cyclopentanoibl thiophene I) TEA ---------------------> Et-O/· ) En , ηu ino 1. ini!, Λ PIC 531 (a) Ethyl 3-cyclopentanonecarboxylate (10 g, 65 mmol), t-butyl cyanoacetate (9.4 g, 65 mmol), sulphur (2.15 g, 65 mmol) and triethylamine (6.58 g, 65 mmol) were heated together in dimethyl-formamide at 100°C for 4 hours. The solvent was removed under reduced pressure, the residue was dissolved in ethyl acetate (50 ml), washed with water (5 x 20 ml), dried (MgSC>4) and concentrated under reduced pressure. The residue was purified by flash chromatography (gradient elution with hexane/ethyl acetate) to give a mixture of 2-amino-3-tbutoxycarbonyl-5-ethoxycarbonyl-cyclopentano[b]thiophene and 2-amino-3-t-butoxycarbonyl-6-ethoxycarbonylcyclopentano[b]thiophene (5.0 g, 25%). 1H NMR (300 MHz, CDCip δ = 1.15(3H,t,J = 7Hz), 1.5(9H,s), 2.6-3.4 (5H,m), 4.2(2H,q,J = 7Hz) p.p.m. (b) The aminothiophenes (5.0 g, 16 mmol) from (a) above, 4-chloro-3-nitropyridine (2.55 g, 16 mmol) and sodium bicarbonate (1.35 g, 16 mmol) were stirred together in ethanol (50 ml) under nitrogen for 48 hours. The mixture was concentrated under reduced pressure and partitioned between ethyl acetate and water. The organic phase was separated, dried (MgSC>4) and concentrated under reduced pressure to give a residue which was purified by flash chromatography PLC 531 IE 9129IK> (gradient elution with dichloromethane/methanol) to give a mixture of 3-t-butoxycarbonyl-5-ethoxycarbonyl2- (3-nitropyrid-4-ylamino)cyclopentano[b]thiophene and 3- t-butoxy-carbonyl-6-ethoxycarbonyl-2-(3-nitropyrid4- ylamino)cyclopentano[b]thiophene (2.6 g, 37%). 1H NMR (300 MHZ, CDCip isomer: & = 1.3(3H,t,J=7Hz), 1.6(9H,s), 3.4(4H,m), 3.7(lH,m), 4.25(2H,q,J = 7Hz), 7.6(lH,d,J = 5Hz), 8.5(lH,d,J = 5Hz), 9.4(lH,s)p.p.m. isomer: S = 1.3(3H,t,J = 7Hz), 1.6(9H,s), 2.7(2H,q), 3.0(2H,m), 4.1(lH,t,J = 5Hz), 7.6(lH,d,J = 5Hz), 8.5(lH,d,J = 5Hz), 9.4(lH,s) p.p.m. (c) The aminonitropyridines (2.5 g, 5.8 mmol) (from (b) above) were dissolved*in ethanol (50 ml) and hydrogenated at 50 p.s.i. and 20°C over 10% palladium on carbon (250 mg) for 3 hours. The catalyst was filtered off and the filtrate concentrated under reduced pressure to give a mixture of 2-(3-aminopyrid4-ylamino)-3-t-butoxycarbonyl-5-ethoxy-carbonylcyclopentano[b]thiophene and 2-(3-aminopyrid-4-ylamino)3-t-butoxycarbonyl-6-ethoxycarbonyl-cyclopentano[b]thiophene (2.1 g, 90%).

PLC 531 ‘ή NMR (300 MHz, CDC13). -isomer: δ = 1.3(3H,t,J = 7Hz), 1.6(9H,s), 1.8(2H,br s) , 3.1-3.4(4H,m), 3.65(lH,m), 4.2(2H,q), 7.4(lH,d,J= 5Hz), 8.1(lH,d,J = 5Hz), 8.13(lH,s), 1O.O6(1H, br s) p.p.m. 4-isomer: δ = 1.3(3H,t,J = 7Hz), 1.60(9H,s), 2.70(2H,m), 3.00(2H,m), 3.56(2H,br s), 4.05(lH,m), 4.20(2H,q J = 7Hz), 7.42(lH,d,J = 5Hz), 8.12(lH,d, J = 5HZ), 8.13(lH,s), 10.12(lH, brs). (d) The diaminopyridines (2.1 g, 5.2 mmol) (from (c) above), were heated in a mixture of acetic acid (50 ml) and acetic anhydride (50 ml) at reflux for 1 hour. The excess of reagents was removed under reduced pressure and the residue was dissolved in ethyl acetate (50 ml) amd washed with saturated aqueous sodium bicarbonate (2 x 30 ml). The organic layer was separated, dried (MgSO^), and concentrated under reduced pressure and the residue was purified by flash chromatography (gradient elution with dichloromethane/methanol) to give a mixture of 3-t-butoxycarbonyl-5-ethoxycarbonyl2—(2-methylimidazo[4,5-c]pyrid-l-yl)cyclopentano[b]thiophene and 3-t-butoxycarbonyl-6-ethoxycarbonyl2-(2-methyl-imidazo[4,5-c]pyrid-l-yl)cyclopentano[b] thiophene (1.5 g, 68%).

PLC 531 1H NMR (300 MHZ, CDC13). isomer: <5 = 1.00(9H,s), 1.28(3H,t,J = 7Hz) , 2.48(3H,S), 3.40(5H,m), 4.2(2H,q,J = 7Hz), 7.05(lH,d,J = 5Hz), 8.32(lH,d,J = 5Hz), 8.95(1H,s)p.p.m. isomer: 6 = 1.00(9H,s), 1.28(3H,t,J = 7Hz), 2.45(3H,s), 2.7-3.2(4H,m), 4.2(2H,q,J = 7Hz, and lH,m), 7.00(lH,d,J = 5Hz), 8.35(lH,d,J = 5Hz), 8.95(lH,s)p.p.m. (e) The t-butylesters (1.5 g, 3.5 mmol) (from (d) above) were dissolved in trifluoroacetic acid and stirred at room temperature for 1 hour. The solvent was removed under reduced pressure, and the residue partitioned between ethyl acetate and saturated aqueous sodium bicarbonate. The aqueous phase was washed with ethyl acetate and acidified with acetic acid, and Λ extracted with ethyl acetate. The combined extracts were dried (MgSO^) and concentrated under reduced pressure to give a mixture of 5-ethoxycarbonyl-2 (2-methylimidazo[4,5-c]pyrid-l-yl)cyclopentano[b] thiophene-3-carboxylic acid and 6-ethoxycarbonyl-2-(2methylimidazo[4,5-c]pyrid-l-yl)cyclopentano[b] thiophene-3-carboxylic acid (1.1 g, 84%).

PLC 531 1H NMR (300 MHz, CDCip. isomer: S = 1.3(3H,t,J = 7Hz), 2.62(3H,s), 3.40(4H,m), 3.75(lH,m), 7.41(lH,d), 8.40(lH,d), 8.82(1H,s) p.p.m. isomer: δ = 1.3(3H,t,J = 7Hz), 2.60(3H,s), 2.80(2H,m), 3.2(2H,ra), 4.2(2H,q,J = 7Hz and lH,m), 7.43(lH,d), 8.40(lH,d), 8.82(lH,s) p.p.m. (f) The carboxylic acids (100 mg, 0.27 mmol) (from (e) above), were dissolved in quinoline (1 ml) and copper powder (50 mg) was added. The mixture was heated under reflux for 1 hour, cooled, poured into water (10 ml) and extracted with ethyl acetate (3 x 15 ml). The combined extracts were washed with concentrated aqueous ammonia (20 ml) and water (20 ml) , dried (MgSC>4) and concentrated under reduced pressure. The residue was purified by flash chromatography (gradient elution with dichloromethane/methanol) to give a mixture of -ethoxycarbonyl-2-(2-methylimidazo[4,5-c]pyrid-l-yl)cyclopentano[d]thiophene and 6-ethoxycarbonyl-2(2-methyl-imidazo[4,5-c]pyrid-l-yl)cyclopentano[b] thiophene (40 mg, 45%).

The hydrochloride salt had m.p. 210-220°C.

PLC 531 Analysis %: Found: C,55.28; H,5.19; N,11.24.

C17H17N3O2S.HC1.1/4 H20 requires C,55.43; H,5.02; N,11.41%. 1H NMR (DMSO-d,.) D -isomer; 6 = 1.3(3H,t), 2.6(3H,s), 3.2(4H,m), 3.8(lH,m), 4.15(4H,q), 7.8(lH,d), 8.6(lH,d), 9.4(lH,s) p.p.m. 4-isomer: S = 1.3(3H,t), 2.6(3H,s), 3.0(2H,m), 2.8(2H,m), 4.15(4H,q), 4.40(lH,t), 7.8(lH,d), 8.6(lH,d), 9.4(lH,s) p.p.m.

Example 20 2-Γ 2-Methvlimidazo(4,5-c)pyrid-l-yl1 cyclopentanoiblthiophene 5 and 6-carboxylic acids \ s PLC 531 A mixture of 5-ethoxycarbonyl-2-(2-methylimidazo[4,5-c]-pyrid-l-yl)cyclopentano[b]thiophene and 6-ethoxycarbonyl-2-(2-methylimidazo[4,5-c]pyrid-l-yl) cyclopentano[b]thiophene (Example 18, 350 mg, 1.07 mmoles) was dissolved in a mixture of ethanol (3 ml) and sodium hydroxide (80 mg, 2.0 mmole) in water (2 ml) was added. The mixture was stirred for 3 hours at room temperature then evaporated to low volume in vacuo and acidified to pH 4.5 with acetic acid. Continuous extraction with CH2C12 gave the product (300 mg, 93%), m.p. 320°C.

Analysis %:Found: C,60.58; Η,4.21; Ν,ΙΙ.01.

C15H13N3°2S re<3uirGS C,60.20; H,4.35; N,10.70.

Example 21 2-(2-MethylimidazoΓ 4,5-c1pyrid-l-yl)-5-(4-morpholinocarbonyl)cyclopentanoTblthiophene and 2-(2methylimidazor 4,5-c]pvrid-l-vl)-6-(4-morpholino carbonyl)cyclopentanofblthiophene A mixture of 2-(2-methylimidazo[4,5-c]pyrid-l-yl)cyclopentano[b]thiophene-5-carboxylic acid and 2-(2-methylimidazo[4,5-c]pyrid-l-yl)cyclopentano[b] thiophene-4-carboxylic acid (100 mg, 0.33 mmol) was stirred together with a solution of oxalyl chloride (50 μΐ, 0.57 mmol) and dimethyl formamide (1 drop) in dry dichloromethane (5 ml) at room temperature for 1 hour.

PIC 531 The solution was concentrated under reduced pressure and the residue dried in vacuo. The acid chloride thus formed was redissolved in dry dichloromethane (3 ml) and added to a solution of morpholine (300 mg, 3.45 mmol) in dry dichloromethane (5 ml) at 0°C. The mixture was allowed to warm to room temperature and was stirred for a further 1 hour. The mixture was poured into water (20 ml), and the aqueous phase was extracted with dichloromethane (3 x 10 ml). The combined extracts were dried (MgSO^), concentrated under reduced pressure, and the residue was purified by flash chromatography (gradient elution with dichloromethane/methanol) to give the title compounds (45 mg, 37%).

Analysis %:- (as fumarate salt, m.p. 232-240°C).

Found: C,56.96; H,5.13; N,11.45.

* CH__N0_S.CH.O requires C,57.02; H,4.96; N,11.57. 4 2 4 4 4 Examples 22 and 23 The compounds of Table 2 were made by the method of Example 21 using diethylamine and 2-aminopyridine instead of morpholine.

Table

Claims (32)

1. A compound of formula (I): wherein X is -CH=CH- or S; R 1 is -COOR 3 , -CN, -CONR 4 R 5 or -NR 6 COR 3 3 . where R is Η, alkyl, C^-C? cycloalkyl, or C 1 ~C 4 alkyl substituted by phenyl; 4 5 R and R are each independently H, C^-Cg alkyl which may optionally be substituted by a hydroxyl or ^-C alkoxy group, C^-C? cycloalkyl, phenyl or pyridyl, said phenyl and pyridyl groups being optionally substituted by up to three groups independently selected from halo, hydroxy, -CF , C 2 -C 4 alkyl and C^-^ alkoxy, or R and 5 . · R together with the nitrogen atom to which they are attached represent a pyrrolidine, piperidine or morpholine ring; R 6 is H or alk yl ; and R is H, halo, or alkyl; or a pharmaceutically acceptable salt thereof. . 1 .

2. A compound according to claim 1, m which R is at the 2-position of the indane nucleus when X is -CH=CHor at the 5-position of the cyclopentanothiophene nucleus when X is -S-.

3. A compound according to claim 1 or 2, in which R 1 is a cyano, carboxy or ethoxycarbonyl group.

4. A compound according to claim 1 or 2, in which R 1 4 5 4 5 is a-CONR R group where R and R together form a piperidino or morpholino group.

5. A compound according to claim 1 or 2, in which R 1 4 5 4 5 . is a-CONR R group and R and R are independently selected from H, t-butyl, cyclopentyl, cyclohexyl, methyl, ethyl, propyl, isopropyl, pyridyl and pyridyl substituted by a methyl group. 5 .

6. A compound according to claim 5, m which R is H.

7. 2-(2-methylimidazo[4,5-c]pyrid-l-yl)-5-(N-pyrid2-yl-carbamoyl)-cyclopentano[b]-thiophene.

8. 2—(Ν,Ν-dipropylcarbamoyl)-5-(2-methylimidazo[4,5-c]pyrid-l-yl)indane.

9. 2-(Ν,Ν-dicyclopentylcarbamoyl)-5-(2-methylimidazo [4,5-c]pyrid-l-yl) indane.

10. A composition comprising a compound according to any preceding claim or a pharmaceutically acceptable salt thereof and a pharmaceutical carrier or excipient.

11. A compound according to any one of claims 1 to 9 or a pharmaceutically acceptable salt thereof, for use in medicine.

12. Use of a compound according to any one of claims 1 to 9 or a pharmaceutically acceptable salt thereof for making a medicament for antagonising platelet activating factor.

13. A compound of formula (IV): (IV) . 2 . . . wherein R is as defined m claim 1.

14. A method of making a compound of formula (I) or a pharmaceutically acceptable salt thereof: ] CH 1\ wherein X is -CH=CH~; R 1 is -COOR 3 , -CN, -CONR 4 R 5 or -NR 6 COR 3 3 . where R is H, C^-Cg alkyl, c 3 _c 7 cycloalkyl, or C^-C^ alkyl substituted by phenyl; 4 5 R and R are each independently H, C -C 6 alkyl which may optionally be substituted by a hydroxyl or alkoxy group, C 3 -C ? cycloalkyl, phenyl or pyridyl, said phenyl and pyridyl groups being optionally substituted by up to three groups independently selected from halo, hydroxy, -CF 3 , C^-C^ alkyl and c ^~ c 4 alkoxy, or R and R together with the nitrogen atom to which they are attached represent a pyrrolidine, piperidine or morpholine ring; R 6 is H or C 1 ~C 4 alkyl; and R is H, halo, or alkyl; or a pharmaceutically acceptable salt thereof; which comprises cyclising a compound of formula (II): wherein R is as defined above and if necessary: i) hydrolysing the compound of formula (I) produced to give a compound of formula (III): (III) ii) esterifying the compound of formula (III) to 3 . produce a compound of formula (I) in which R is C^-Cg alkyl, cycloalkyl or C -C 4 alkyl substituted by phenyl, iii) converting the compound of formula (III) to its carbonyl halide and treating the carbonyl halide with 4 5 an amine of formula HNR R or a salt thereof to produce λ . 1 . 4 5 a compound of formula (I) in which R is -CONR R , iv) converting the compound of formula (III) to an amine of formula (IV) by treatment with an azide followed by hydrolysis of the product and treating the amine with a carbonyl halide of formula R COY where Y is a halogen to produce a compound of formula (I) in which R 1 is -NHCOR 3 , v) treating the compound from (iv) with an alkyl halide to produce a compound of formula (I) in which R 1 is -NR 6 COR 3 where R 6 is alkyl, and (vi), forming a salt of the compound produced.

15. A method of making a compound of formula (I) or a pharmaceutically acceptable salt thereof: wherein X is -S-; R 1 is -COOR 3 , -CN, -CONR 4 R 5 or -NR 6 COR 3 where R 3 is H, ^-Cg alkyl, C 3 -C ? cycloalkyl, or C 1 ~C 4 alkyl substituted by phenyl; 4 5 R and R are each independently H, c 1 -c 6 alkyl which may optionally be substituted by a hydroxyl or C -C alkoxy group, C 3 ~C 7 cycloalkyl, phenyl or pyridyl, said phenyl and pyridyl groups being optionally substituted by up to three groups independently selected from halo, hydroxy, -CF 3 , C 3 -C 4 alkyl and C 1 ~C 4 alkoxy, or R and R together with the nitrogen atom to which they are attached represent a pyrrolidine, piperidine or morpholine ring; R 6 is H or c 1 -c 4 alkyl; 2 . and R is H, halo, or c 1~ c 4 alkyl; or a pharmaceutically acceptable salt thereof, which comprises cyclising a compound of formula (VII) . 3 . wherein R is C-^-Cg alkyl, c 3 _c 7 cycloalkyl or C 1 ~C 4 7 . alkyl substituted by phenyl, and R is an optionally substituted alkyl group VII and replacing the -CC> 2 R gtoup by H; and if necessary i) hydrolysing the compound of formula (I) produced 3 . to give a compound of formula (I) m which R is H, ii) converting the compound obtained from i) to its carbonyl halide and treating the product with an 4 5 amine of formula HNR R or a salt thereof to produce a compound of formula (I) in which R 1 is 4 5 -CONR R , PIC 531 iii) converting the compound from (i) to an amine by treatment with an azide followed by hydrolysis of the product, and treating the amine with a . 3 carbonyl halide of formula R COY when Y is a halogen to produce a compound of formula (I) in which R 1 is -NHCOR 3 , iv) treating the compound from iii) with an alkyl halide to produce a compound of formula (I) in which R is -NR COR where R is alkyl, v) converting the compound of formula (I) in which R 3 3 ... is -COOH or -COOR to the corresponding nitrile, and vi) forming a salt of the compound produced.

16. A method according to claim 14 or 15, in which the compound of formula (II) or (VII) is cyclised by heating with acetic anhydride and acetic acid.

17. A method according to claim 14, 15 or 16, in which R 3 is at the 2-position of the indane nucleus when X is * -CH=CH- or at the 5-position of the cyclopentano thiophene nucleus when X is -S-.

18. A method according to any one of claims 14 to 17, in which R 3 is a cyano, carboxy or ethoxycarbonyl group in the compound obtained.

19. A method according to any one of claims 14 to 17, 1 4 5 4 5 in which R is a-CONR R group where R and R together form a piperidino or morpholino group in the compound obtained. PLC 531

20. A method according to any one of claims 14 to 17, 1 4 5 4 5 in which R is a-CONR R group and R and R are independently selected from H, t-butyl, cyclopentyl, cyclohexyl, methyl, ethyl, propyl, isopropyl, pyridyl and pyridyl substituted by a methyl group in the compound obtained. 5 .

21. A method according to claim 20, in which R is H.

22. A method according to claim 15, in which the compound is 2-(2-methylimidazo[4,5-c]pyrid-l-yl)-5(N-pyrid-2-yl-carbamoyl)-cyclopentano[b)-thiophene.

23. A method according to claim 14, in which the compound is 2-(Ν,Ν-dipropylcarbamoyl)-5-(2methy1imidazo-[4,5-c)pyrid-l-yl) indane.

24. A method according to claim 14, in which the compound is 2-(N,N-dicyclopentylcarbamoyl)-5-(2methylimidazo[4,5-c]pyrid-l-yl)indane.

25. A compound of the formula (I) given and defined in claim 1 or a pharmaceutically acceptable salt thereof, which is any one of those specifically hereinbefore mentioned other than a compound as claimed in claims 7-9.

26. A composition according to claim 10, substantially as hereinbefore described.

27. Use according to claim 11, substantially as hereinbefore described.

28. Use according to claim 12, substantially as hereinbefore described.

29. A compound of the formula (IV) given and defined in claim 13 which is specifically hereinbefore mentioned.

30. A method according to claim 14, substantially as hereinbefore described and exemplified.

31. A method according to claim 15, substantially as hereinbefore described and exemplified.

32. A compound of the formula (I) given and defined in claim 14 or 15 or a pharmaceutically acceptable salt thereof, whenever made by a method claimed in any one of claims 14-24, 30 or 31.